Sage Therapeutics

ZULRESSO

Manufacturer:

Sage Therapeutics

Zulresso HCPCS:

J1632

HCPCS Code Descriptor:

Injection, brexanolone, 1 mg

Category:

J Code

Zulresso NDCs:

72152-0547-20

Primary Type:

Anti-Depressant

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Zulresso:

ZULRESSO is an Anti-Depressant drug manufactured by Sage Therapeutics and administered via the Intravenous route of administration. The J Code: J1632 is aligned to the drug ZULRESSO.

ACCESS PRICING AND MORE BY REGISTERING

J1632 Added Date:

October 1, 2020

J1632 Effective Date:

January 1, 2023

J1632 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Zulresso billing and coding information.
Zulresso patient assistance information can be found through Sage Central at the URL: https://www.sagecentralsupport.com/zulressoforhealthcareproviders/
ZULRESSO prescribing information can be found at the link below:
Information regarding ZULRESSO’s side effects can be found at MedlinePlus